Pipeline

Ashvattha’s technology platform consists of hydroxyl dendrimers that selectively target actively endocytosing cells such as reactive microglia and macrophages responsible for chronic inflammation and disease progression within the body.  Quiescent macrophage and other non-endocytosing cells do not take up the hydroxyl dendrimer.

Benefits of HD Therapeutics

  • Treat a broad range of diseases. With many known cellular pathways, it will be possible to design HDTs to alter the cells for the beneficial treatment of each disease
  • Target disease from systemic treatment (injection or oral) that cannot be targeted effectively by existing drug classes. Many small molecules and therapeutic proteins, including monoclonal antibodies, are not sufficiently selective or do not target only the diseased tissues. HDTs have been shown to selectively target reactive cells in diseased tissues
  • Increased potency and duration of action. Each HDT contains several drug molecules covalently conjugated to a single HD. As a result, one HDT can be very effective in altering one or more intracellular pathways. HDTs remain inside the target cells for up to one month providing a sustained localized effect without systemic exposure
  • Inexpensive to manufacture. Large scale (>1kg GMP lots) enable very competitive COGS and opens up new geographic market opportunities

Hydroxyl Dendrimer (HD)

4-6 nanometers
~ ½ size of antibody

Water-like Surface
Precision Targeting
No Ligand Needed

Benefits of HD Therapeutics

  • Treat a broad range of diseases. With many known cellular pathways, it will be possible to design HDTs to alter the cells for the beneficial treatment of each disease
  • Target disease from systemic treatment (injection or oral) that cannot be targeted effectively by existing drug classes. Many small molecules and therapeutic proteins, including monoclonal antibodies, are not sufficiently selective or do not target only the diseased tissues. HDTs have been shown to selectively target reactive cells in diseased tissues
  • Increased potency and duration of action. Each HDT contains several drug molecules covalently conjugated to a single HD. As a result, one HDT can be very effective in altering one or more intracellular pathways. HDTs remain inside the target cells for up to one month providing a sustained localized effect without systemic exposure
  • Inexpensive to manufacture. Large scale (>1kg GMP lots) enable very competitive COGS and opens up new geographic market opportunities

Hydroxyl Dendrimer (HD)

4-6 nanometers
~ ½ size of antibody

Water-like Surface, Precision Targeting, No Ligand Needed